Status:
COMPLETED
Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis
Lead Sponsor:
Pfizer
Conditions:
Plaque Psoriasis
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to compare the safety and efficacy of different doses of etanercept for the treatment of moderate to severe psoriasis.
Eligibility Criteria
Inclusion
- 18 years of age or older at time of consent.
- Active, moderate to severe chronic plaque psoriasis defined by the following criteria: Clinically stable, plaque psoriasis involving greater than or equal to 10% body surface area (BSA) or PASI greater than or equal to 10.
- In the opinion of the investigator, failure, intolerance, contraindication or not a candidate for the following: Methotrexate (MTX), cyclosporine and psoralen plus ultraviolet A radiation (PUVA) therapy.
Exclusion
- Evidence of skin conditions (e.g., eczema) other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis.
- Rheumatologic disease such as rheumatoid arthritis, systemic lupus erythematous, systemic vasculitis, scleroderma and polymyositis, or associated syndromes.
- Active or recent (within 2 years) tuberculosis (TB) infection.
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
273 Patients enrolled
Trial Details
Trial ID
NCT00663052
Start Date
June 1 2008
End Date
January 1 2010
Last Update
April 23 2012
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Capital Federal, Buenos Aires, Argentina, 01114
2
Pfizer Investigational Site
Capital Federal, Buenos Aires, Argentina, 01199
3
Pfizer Investigational Site
San Miguel, Buenos Aires, Argentina, 1684
4
Pfizer Investigational Site
Feldkirch, Austria